News
Innovative Pathways in Drug Discovery: Integrating DNA-Encoded Library (DEL) Technology
Highlight

Decoding the Future of Drug Discovery: Integrating DNA-Encoded Library(DEL)Technology into FlC Drug Discovery

Discovery of indoleamine 2,3.dioxygenase (lDO1) Inhibitors that Utilize Unique Binding Mode

V-DEL Platform Competitive Advantages

DEL played a pivotal role in the IDO1 campaign

On December 13th, 2023, Viva Biotech hosted a Viva BioInsights webinar, centered on the theme “Innovative Pathways in Drug Discovery: Integrating DNA-Encoded Library (DEL) Technology”. Dr. Bing Xia, Vice President of Viva Biotech, and Dr. Wes Kazmierski, a Medicinal Chemist attended and discussed the application of DEL technology, emphasizing how DEL technology accelerates the R&D process and sharing the case study of identifying a Best in Class (BIC) IDO1 inhibitor.

 

Dr. Xia Bing: DEL screening plays a significant role in both FIC drugs development and BIC drugs evolution. Through clinical experiments, we have identified IDO1 is a very DEL-friendly target. However, we also found a significant difference in chemotype in biochemical assays, which requires further examination.

 

Dr. Wes Kazmierski: IDO1 inhibition had been a very crowded and competitive area of pharmaceutical research and development, but initial clinical IDO1 inhibitors were characterized by less than desirable potency and pharmacokinetic properties. We need to discover new chemotypes to address this issue.

 

Click the video for more.

Introduction
Bing, Xia
Vice President& Head of Early Discovery Platforms

Ph.D., Boston University, with the widely recognized photochemist, Prof. Guilford Jones, collaborated with Prof. John Porco. Worked with GlaxoSmithKline (Boston, USA) and was selected as GSK Associate Fellow, with 15+ years of experience in DNA Encoded Library (DEL) R& D. Led a variety of projects across wide range of therapeutic areas such as oncology, CNS, immunology, and infectious diseases/HIV. Won 3 Exceptional Science Awards, 2 Cool Chemistry Finalists, 5 Silver awards and 10 Bronze Awards. Finalist for the GSK $5K Electroceutical Ideation Challenge/$1million InnoCentive (reviewed by Draper Lab).Organizing committee, GSK 2019 Global Chemistry Conference (April 2019, London, UK).Organizing committee, the 8th International Symposium on DNA-Encoded Chemical Libraries (Oct. 2018, Chengdu, China)Published 20+ articles, book chapters, and patents in various fields in esteemed journals, such as Nature Comm., JACS, J. Med. Chem. As a special reviewer, reviewed >100 submissions for 19 high impact journals.

Dr. Wes Kazmierski
Medicinal Chemist

Dr. Wes Kazmierski is a medicinal chemist and drug discovery scientist with many years of experience in academia and industry. He co-developed the one-peptide one-bead library approach at Selectide Corp. He led many discovery and lead optimization programs at GlaxoSmithKline and ViiV Healthcare, delivering a number of clinical-stage compounds and was named a co-inventor of drug Lexiva. He was selected a GSK Fellow, and in addition to many others, received four GSK Gold Awards for enabling clinical programs. He is currently a Senior Director at Biohaven Pharmaceuticals. His chemistry expertise includes small molecule receptor binders, enzyme inhibitors, protein degraders, peptides and mimetics, protein drugs, bifunctional antibodies, antibody drug-conjugates. His therapeutic experience includes virology, cancer, immunology, neurology and autoimmune diseases. He co-authored more than 200 peer-reviewed publications and patents. His talk will summarize IDO1 inhibitors discovery at GSK/ViiV.

Content you may be interested
Online Message
Thank you for your interest and support for Viva Biotech.

For video replay,please provide the following details.

×